Filing Flows › Editas Medicine (EDIT) › Q3 2026 › vs Q3 2025
Editas Medicine (EDIT) Q3 2026 vs Q3 2025 (year over year)
Editas Medicine's revenue rose $2.8M (+37%) from $7.5M in Q3 2025 to $10.4M in Q3 2026.
Editas Medicine, Q3 2026: revenue $10.4M (+37% year over year), operating margin -234.3%, net loss $23.4M, operating cash flow −$21.2M. The chart draws each line against Q3 2025, the increases inside each band.
Every line
| Line | Q3 2026 | Q3 2025 | Change | % |
|---|---|---|---|---|
| Revenue | $10.4M | $7.5M | $2.8M | +37% |
| Other income, net | $889K | −$569K | $1.5M | — |
| Net loss | $23.4M | $25.1M | −$1.7M | -7% |
| Costs & expenses | $34.6M | $32.7M | $2.0M | +6% |
| Operating costs | $34.6M | $32.1M | $2.6M | +8% |
| Research & development | $21.2M | $19.8M | $1.4M | +7% |
| General & admin | $13.5M | $12.3M | $1.2M | +9% |
| Operating cash sources | $24.1M | $33.8M | −$9.6M | -29% |
| Depreciation | $385K | $721K | −$336K | -47% |
| Share-based compensation | $2.6M | $2.2M | $343K | +15% |
| Cash used in operations | $21.2M | $30.8M | −$9.7M | -31% |
| Net loss absorbed | $23.4M | $25.1M | −$1.7M | -7% |
| Working capital & other | $753K | $8.7M | −$7.9M | -91% |
Questions
How much did Editas Medicine's revenue grow year over year in Q3 2026?
Editas Medicine's revenue rose $2.8M (+37%) from $7.5M in Q3 2025 to $10.4M in Q3 2026.